🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesHas anyone dealt with blood pressure reduction mechanisms on glp-1? Page 5

Has anyone dealt with blood pressure reduction mechanisms on glp-1?

ZaraB_AL Mon, Jul 22, 2024 at 12:53 PM 53 replies 2,492 viewsPage 5 of 11
carl_compliance
Member
234
1,123
Nov 2024
Raleigh, NC
Jul 28, 2024 at 12:50 PM#21

Adding the clinical framing, because it changes how the question reads.

Vitamin deficiency cascade with cardiovascular risk: after 6+ months of reduced food intake, I developed a subtle but important pattern: low B12 → elevated homocysteine → increased cardiovascular risk marker.

The connection: B12 is a cofactor for homocysteine metabolism. Without adequate B12, homocysteine accumulates. This is ironic — taking a CV-protective medication while developing a CV risk factor from reduced nutrition.

Solution: comprehensive vitamin supplementation and regular lab monitoring. Don't let the medication's benefits be undermined by nutritional deficiencies.

Last edited: Jul 28, 2024 at 3:50 PM
50 23labquiet_amy, emily_PDX, Dr.SleepRoch and 47 others
Reply Quote Save Share Report
jim_asheville
Member
289
1,234
Aug 2024
Asheville, NC
Jul 29, 2024 at 9:00 PM#22
carl_compliance said:
Vitamin deficiency cascade with cardiovascular risk: after 6+ months of reduced food intake, I developed a subtle but important pattern: low B12 →…

Can confirm. Same sequence, different timescale.

Last edited: Jul 30, 2024 at 12:00 AM
1 24BenResearch_OR
Reply Quote Save Share Report
mel_PDX
Member
189
890
Dec 2024
Portland, OR
Jul 31, 2024 at 5:10 AM#23
carl_compliance said:
Vitamin deficiency cascade with cardiovascular risk: after 6+ months of reduced food intake, I developed a subtle but important pattern: low B12 →…

Lp(a) and cardiovascular risk: a nuance that matters. Unlike most lipid markers, Lp(a) is 90%+ genetically determined and doesn't really change with weight loss or GLP-1 therapy.

My Lp(a) has remained at 51 nmol/L across all time points. If yours is elevated (>50 nmol/L), you need additional risk mitigation strategies regardless of your GLP-1 response. Don't assume your medication is covering all cardiovascular risk factors.

2 0PeptideSynthNJ, Dr.KarenChen
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
NicoleRaleigh
Member
356
1,567
Aug 2024
Raleigh, NC
Aug 1, 2024 at 1:19 PM#24
carl_compliance said:
Vitamin deficiency cascade with cardiovascular risk: after 6+ months of reduced food intake, I developed a subtle but important pattern: low B12 →…

Continuous metabolic monitoring dashboard for cardiovascular risk — I track everything in a spreadsheet and here's the month-over-month trend for my key markers:

Weight: consistent downtrend, -1.5 lbs/week average
Fasting glucose (finger stick): stable at 86 mg/dL
Blood pressure (home): 115/72 average
Resting heart rate: 66 bpm (down from 82)
Waist circumference: down 16 inches total

The resting heart rate improvement correlates with cardiovascular fitness gains. Everything is moving in the right direction.

3 1VendorMark, COA_Karl, MikeFit_NJ
Reply Quote Save Share Report
fiona_glasgow
Member
312
1,345
Aug 2024
Glasgow, UK
Aug 2, 2024 at 9:27 PM#25

Following on from carl_compliance — and this may be the naive question:

How long did you give it before you decided it was working?

4 2NeuroNate, JessicaH_TX, KevinCompounds and 1 other
Reply Quote Save Share Report
13456711

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register